Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.23 CAD | 0.00% | +9.52% | +9.52% |
Apr. 08 | Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding | CI |
Mar. 28 | Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 42M 57.46M |
---|---|---|---|---|---|
Net income 2022 | -6M -8.21M | Net income 2023 | -6M -8.21M | EV / Sales 2022 | - |
Net cash position 2022 | 784K 1.07M | Net cash position 2023 | 808K 1.11M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.33
x | P/E ratio 2023 |
-6.45
x | Employees | 9 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.24% |
1 week | +9.52% | ||
Current month | +4.55% | ||
1 month | +24.32% | ||
3 months | +35.29% | ||
6 months | -2.13% | ||
Current year | +9.52% |
Managers | Title | Age | Since |
---|---|---|---|
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Director of Finance/CFO | 59 | Feb. 13 | |
Chief Tech/Sci/R&D Officer | - | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 22-04-17 | |
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Malgorzata Laube
BRD | Director/Board Member | - | 22-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 0.23 | 0.00% | 500 |
24-05-08 | 0.23 | +4.55% | 1,000 |
24-05-06 | 0.22 | +7.32% | 1,000 |
24-05-03 | 0.205 | -2.38% | 509 |
24-05-02 | 0.21 | -4.55% | 198,500 |
Delayed Quote Toronto S.E., May 09, 2024 at 09:30 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 38.46M | |
+25.03% | 46.71B | |
+48.83% | 41.8B | |
-1.02% | 41.52B | |
-5.86% | 29.55B | |
+10.54% | 25.78B | |
-20.47% | 19.26B | |
+2.20% | 12.14B | |
-2.96% | 12.08B | |
+28.20% | 11.98B |
- Stock Market
- Equities
- HBP Stock